Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001567619-22-006226 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-03 | 2022-03-01 | ARQT | Lock Kenneth A. | Chief Commercial Off | S - Sale | $17.75 | -935 | 31.7K | -3% | -$16.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | S | D | 935 | $17.75 | 31,734 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 1,002 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 964 shares on May 31, 2021 and 38 shares on November 30, 2021. (F4) Includes 14,000 RSUs. |